Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea | BMC Cancer | Full Text

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea | BMC Cancer | Full Text

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

Anti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhib...

Authors:Hyera Kim, Minsuk Kwon, Binnari Kim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park and Myung-Ju Ahn

Citation:BMC Cancer 2020 20:727

Content type:Research article

 

Published on: 5 August 2020

• ViewFull Text
 
• ViewPDF